The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TGTX | +50.66% | +28.98% | +5.22% | +2,991% |
| S&P | +14.84% | +96.04% | +14.41% | +436% |
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $141.15M | 92.1% |
| Gross Profit | $122.15M | 87.7% |
| Gross Margin | 86.54% | -2.1% |
| Market Cap | $28.57B | 107.8% |
| Market Cap / Employee | $81.16M | 0.0% |
| Employees | 352 | 0.0% |
| Net Income | $28.19M | 309.8% |
| EBITDA | $34.90M | 292.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $129.13M | 55.7% |
| Accounts Receivable | $231.52M | 176.9% |
| Inventory | 155.2 | 91.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $252.63M | 127.1% |
| Short Term Debt | $1.09M | -16.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 10.95% | -19.8% |
| Return On Invested Capital | -58.98% | 45.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $7.39M | 33.6% |
| Operating Free Cash Flow | $7.44M | 34.3% |
| Metric | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 29.65 | 215.62 | 161.60 | 96.18 | 39.43% |
| Price to Book | 94.81 | 122.01 | 138.17 | 119.95 | 39.68% |
| Price to Sales | 14.20 | 14.66 | 16.61 | 12.88 | 57.52% |
| Price to Tangible Book Value | 94.81 | 122.01 | 138.17 | 119.95 | 38.99% |
| Price to Free Cash Flow TTM | 109.65 | 41.82 | - | ||
| Enterprise Value to EBITDA | 293.80 | 158.81 | 736.97 | 167.68 | -45.44% |
| Free Cash Flow Yield | 0.9% | 2.4% | - | ||
| Return on Equity | -8.0% | 12.2% | 19.7% | 26.6% | -69.66% |
| Total Debt | $253.81M | $253.72M | $253.71M | $253.72M | 125.45% |
TGTX earnings call for the period ending September 30, 2021.
TGTX earnings call for the period ending June 30, 2021.
TGTX earnings call for the period ending March 31, 2021.
TGTX earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
